INPART Opportunity
An immunology‑focused pharmaceutical company is seeking novel druggable targets and/or molecules that are involved in regulation of immunometabolism in inflammatory disease. Specifically, the team are looking to focus on targetable molecules with demonstrated involvement in human pathology (e.g. a role in pathways linked to disease).
Approaches of Interest:
- Approaches that dramatically alter the immune cell state (e.g. macrophage M1 to M2 transition, or Th1 to Tregtransition)
- Targets that specifically express in immune cells
- Improved modulation of pathways targeted by existing therapeutics
- Modalities of interest are limited to small molecules and orally available peptides
- Assays or platforms to enable discovery of novel targets
- Research related to autoimmune diseases and diseases with clear causality of target and pathology
Out of Scope:
- Submissions related to rheumatoid arthritis or cancer
- Molecules with systemic effects and toxicity concerns
Developmental Stages of Interest:
Research at basic to late preclinical stages is within scope. Research with methodology and identified targets is preferred.
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. The client is also open to novel research proposals which can be outlined using the submission form. In submitting to this campaign, the candidate confirms that the submission contains only non-confidential information.
Opportunity for Collaboration
The client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.
Application deadline: Dec. 13, 11:59 p.m.
The KTO office <kto@sns.it> is available for support.